168 related articles for article (PubMed ID: 23372746)
1. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers.
Lee J; Kim S; Kim P; Liu X; Lee T; Kim KM; Do IG; Park JO; Park SH; Jang J; Hoe N; Harvie G; Kuller A; Jain A; Meyer G; Leesman G; Park YS; Choi MG; Sohn TS; Bae JM; Lim HY; Singh S; Kang WK
PLoS One; 2013; 8(1):e54644. PubMed ID: 23372746
[TBL] [Abstract][Full Text] [Related]
2. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
3. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
4. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
5. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
7. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
8. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.
Yun C; Gang L; Rongmin G; Xu W; Xuezhi M; Huanqiu C
Mol Carcinog; 2015 Dec; 54(12):1700-9. PubMed ID: 25400108
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.
Park CK; Park JS; Kim HS; Rha SY; Hyung WJ; Cheong JH; Noh SH; Lee SK; Lee YC; Huh YM; Kim H
Oncotarget; 2016 Nov; 7(44):72099-72112. PubMed ID: 27765925
[TBL] [Abstract][Full Text] [Related]
10. The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.
Chae YK; Gagliato Dde M; Pai SG; Carneiro B; Mohindra N; Giles FJ; Ramakrishnan-Geethakumari P; Sohn J; Liu S; Chen H; Ueno N; Hortobagyi G; Gonzalez-Angulo AM
PLoS One; 2016; 11(4):e0152585. PubMed ID: 27055285
[TBL] [Abstract][Full Text] [Related]
11. Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients.
Kim P; Liu X; Lee T; Liu L; Barham R; Kirkland R; Leesman G; Kuller A; Ybarrondo B; Ng SC; Singh S
Proteome Sci; 2011 Dec; 9(1):75. PubMed ID: 22172159
[TBL] [Abstract][Full Text] [Related]
12. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
13. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
15. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.
Cao GD; Chen K; Chen B; Xiong MM
BMC Cancer; 2017 Dec; 17(1):841. PubMed ID: 29233126
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
Yu L; Saile K; Swartz CD; He H; Zheng X; Kissling GE; Di X; Lucas S; Robboy SJ; Dixon D
Mol Med; 2008; 14(5-6):264-75. PubMed ID: 18231572
[TBL] [Abstract][Full Text] [Related]
17. A systematic approach to therapeutic target selection in oesophago-gastric cancer.
Paterson AL; Shannon NB; Lao-Sirieix P; Ong CA; Peters CJ; O'Donovan M; Fitzgerald RC
Gut; 2013 Oct; 62(10):1415-24. PubMed ID: 22773546
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.
Ema A; Yamashita K; Ushiku H; Kojo K; Minatani N; Kikuchi M; Mieno H; Moriya H; Hosoda K; Katada N; Kikuchi S; Watanabe M
Cancer Sci; 2014 Dec; 105(12):1591-600. PubMed ID: 25455899
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L; Strommen K; Dao-Pick T; Parry G; Goodman L; Winslow J
Breast Cancer Res; 2011 Apr; 13(2):R44. PubMed ID: 21496232
[TBL] [Abstract][Full Text] [Related]
20. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays.
Gujral TS; Karp RL; Finski A; Chan M; Schwartz PE; MacBeath G; Sorger P
Oncogene; 2013 Jul; 32(29):3470-6. PubMed ID: 22945653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
